Worth reading
31Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
860000
Yen (reimbursement price)Wording
Definitive
How definitive the wording is.Reimbursement coverage approval for the medical device "Cellusion Cell Therapy Kit SUI" for treating male stress urinary incontinence
Subject Entity
ADRセラピューティクス株式会社 (the Company's subsidiary)
Target Locations / Products
Medical device for treating male stress urinary incontinence, “セルーション セルセラピーキット SUI”
Occurrence16 September 2026
Same dayLitigation / administrative action16 September 2026
This disclosure10/15/2026
Related procedures
Type
Reimbursement coverage approval procedure
Court or authority
Central Social Insurance Medical Council (Chuikyo)
| Item | Details |
|---|---|
| Event name | Reimbursement coverage approval for the medical device "Cellusion Cell Therapy Kit SUI" for treating male stress urinary incontinence |
| Date of occurrence | 16 September 2026 |
| Subject Entity | ADRセラピューティクス株式会社 (the Company's subsidiary) |
| Target Locations / Products | Medical device for treating male stress urinary incontinence, “セルーション セルセラピーキット SUI” |
| Type of litigation or proceeding | Reimbursement coverage approval procedure |
| Court or authority | Central Social Insurance Medical Council (Chuikyo) |
| Date of filing / date of action | 16 September 2026 |
Items this document does not state (18)
Date recognized / date notice receivedCauseAmount of Impact on Business PerformanceAccounting period in which recognizedImpact on Earnings ForecastPlaintiffDefendantClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changeOutlookPlanned follow-up disclosure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following deliberations at the Central Social Insurance Medical Council (Chuikyo) plenary meeting held on 16 September 2026, reimbursement coverage was formally approved effective that date.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.